Detail akcie Grifols -A- online

Business Summary: Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Grifols SA revenues increased 9% to EUR7.21B. Net income increased from EUR42.3M to EUR156.9M. Revenues reflect Bioscience segment increase of 11% to EUR6.14B, Bio Supplies segment increase of 35% to EUR215.7M, European Union segment increase of 25% to EUR1.12B, United States/Canada segment increase of 5% to EUR4.09B. Net income benefited from Selling/General/Admin.